Effect of long period treatment with erythropoiesis stimulating agents on clinically and laboratory parameters in hemodialysis autosomal dominant polycystic kidney disease patients

Introduction. The study of dialysis patients not needing erythropoiesis-stimulating agents (ESA) for long periods of time has gained interest lately. The aim of this study was to compare laboratory and clinical parameters in hemodialysis patients with autosomal dominant polycystic kidney disease (AD...

Full description

Bibliographic Details
Main Authors: Orăsan Olga Hilda, Petrov Ljubomir, Urian Laura, Cozma Angela, Ciulei George, Patiu Ioan Mihai, Orăsan Remus Aurel
Format: Article
Language:English
Published: Sciendo 2017-10-01
Series:Romanian Journal of Laboratory Medicine
Subjects:
Online Access:https://doi.org/10.1515/rrlm-2017-0032
_version_ 1831568142050000896
author Orăsan Olga Hilda
Petrov Ljubomir
Urian Laura
Cozma Angela
Ciulei George
Patiu Ioan Mihai
Orăsan Remus Aurel
author_facet Orăsan Olga Hilda
Petrov Ljubomir
Urian Laura
Cozma Angela
Ciulei George
Patiu Ioan Mihai
Orăsan Remus Aurel
author_sort Orăsan Olga Hilda
collection DOAJ
description Introduction. The study of dialysis patients not needing erythropoiesis-stimulating agents (ESA) for long periods of time has gained interest lately. The aim of this study was to compare laboratory and clinical parameters in hemodialysis patients with autosomal dominant polycystic kidney disease (ADPKD) treated or not with ESA. Methods. Forty-six hemodialysis ADPKD patients were studied for 8 months and they were divided into: group 1- 29 patients who received ESA during the study period and group 2- 17 patients with no ESA treatment. The following parameters were determined: weekly treatment time, body mass index (BMI), pre-session diastolic blood pressure (DBP), pre-session systolic blood pressure (SBP), blood volume processed (BVD), interdialytic body weight gain (IBWG), spKt/V -K/DOQI formula (Kt/V), urea distribution volume (UDV), hemoglobin (Hb), ferritin, transferrin saturation (TSAT), serum phosphate, total serum calcium, normalized protein catabolic ratio (nPCR), albumin, and intact parathormone (PTH). Results. Patients not requiring ESA were more likely to be men, had higher Hb, albumin, total serum calcium levels, IBWG, UDV, BVP, and weekly treatment time. They had lower ferritin, TSAT, SBP. There was no difference regarding DBP, BMI, serum phosphate, PTH, Kt/V, and nPCR. Conclusion. Hemodialysis ADPKD patients not treated with ESA seem to be better nourished, with a slightly better SBP control, with longer dialysis time and increased Hb (despite lower iron loading markers), compared to hemodialysis ADPKD patients treated with ESA.
first_indexed 2024-12-17T12:10:44Z
format Article
id doaj.art-06083eb0407940a08fca785c967948c4
institution Directory Open Access Journal
issn 2284-5623
language English
last_indexed 2024-12-17T12:10:44Z
publishDate 2017-10-01
publisher Sciendo
record_format Article
series Romanian Journal of Laboratory Medicine
spelling doaj.art-06083eb0407940a08fca785c967948c42022-12-21T21:49:25ZengSciendoRomanian Journal of Laboratory Medicine2284-56232017-10-0125437538210.1515/rrlm-2017-0032rrlm-2017-0032Effect of long period treatment with erythropoiesis stimulating agents on clinically and laboratory parameters in hemodialysis autosomal dominant polycystic kidney disease patientsOrăsan Olga Hilda0Petrov Ljubomir1Urian Laura2Cozma Angela3Ciulei George4Patiu Ioan Mihai5Orăsan Remus Aurel64th Medical Department, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, RomaniaHemathology Department, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, RomaniaHemathology Department, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania4th Medical Department, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania4th Medical Department, University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, RomaniaNefromed Dialysis Center, Cluj-Napoca, RomaniaNefromed Dialysis Center, Cluj-Napoca, RomaniaIntroduction. The study of dialysis patients not needing erythropoiesis-stimulating agents (ESA) for long periods of time has gained interest lately. The aim of this study was to compare laboratory and clinical parameters in hemodialysis patients with autosomal dominant polycystic kidney disease (ADPKD) treated or not with ESA. Methods. Forty-six hemodialysis ADPKD patients were studied for 8 months and they were divided into: group 1- 29 patients who received ESA during the study period and group 2- 17 patients with no ESA treatment. The following parameters were determined: weekly treatment time, body mass index (BMI), pre-session diastolic blood pressure (DBP), pre-session systolic blood pressure (SBP), blood volume processed (BVD), interdialytic body weight gain (IBWG), spKt/V -K/DOQI formula (Kt/V), urea distribution volume (UDV), hemoglobin (Hb), ferritin, transferrin saturation (TSAT), serum phosphate, total serum calcium, normalized protein catabolic ratio (nPCR), albumin, and intact parathormone (PTH). Results. Patients not requiring ESA were more likely to be men, had higher Hb, albumin, total serum calcium levels, IBWG, UDV, BVP, and weekly treatment time. They had lower ferritin, TSAT, SBP. There was no difference regarding DBP, BMI, serum phosphate, PTH, Kt/V, and nPCR. Conclusion. Hemodialysis ADPKD patients not treated with ESA seem to be better nourished, with a slightly better SBP control, with longer dialysis time and increased Hb (despite lower iron loading markers), compared to hemodialysis ADPKD patients treated with ESA.https://doi.org/10.1515/rrlm-2017-0032autosomal dominant polycystic kidney diseaseerythropoiesis-stimulating agentsanemiahemodialysis
spellingShingle Orăsan Olga Hilda
Petrov Ljubomir
Urian Laura
Cozma Angela
Ciulei George
Patiu Ioan Mihai
Orăsan Remus Aurel
Effect of long period treatment with erythropoiesis stimulating agents on clinically and laboratory parameters in hemodialysis autosomal dominant polycystic kidney disease patients
Romanian Journal of Laboratory Medicine
autosomal dominant polycystic kidney disease
erythropoiesis-stimulating agents
anemia
hemodialysis
title Effect of long period treatment with erythropoiesis stimulating agents on clinically and laboratory parameters in hemodialysis autosomal dominant polycystic kidney disease patients
title_full Effect of long period treatment with erythropoiesis stimulating agents on clinically and laboratory parameters in hemodialysis autosomal dominant polycystic kidney disease patients
title_fullStr Effect of long period treatment with erythropoiesis stimulating agents on clinically and laboratory parameters in hemodialysis autosomal dominant polycystic kidney disease patients
title_full_unstemmed Effect of long period treatment with erythropoiesis stimulating agents on clinically and laboratory parameters in hemodialysis autosomal dominant polycystic kidney disease patients
title_short Effect of long period treatment with erythropoiesis stimulating agents on clinically and laboratory parameters in hemodialysis autosomal dominant polycystic kidney disease patients
title_sort effect of long period treatment with erythropoiesis stimulating agents on clinically and laboratory parameters in hemodialysis autosomal dominant polycystic kidney disease patients
topic autosomal dominant polycystic kidney disease
erythropoiesis-stimulating agents
anemia
hemodialysis
url https://doi.org/10.1515/rrlm-2017-0032
work_keys_str_mv AT orasanolgahilda effectoflongperiodtreatmentwitherythropoiesisstimulatingagentsonclinicallyandlaboratoryparametersinhemodialysisautosomaldominantpolycystickidneydiseasepatients
AT petrovljubomir effectoflongperiodtreatmentwitherythropoiesisstimulatingagentsonclinicallyandlaboratoryparametersinhemodialysisautosomaldominantpolycystickidneydiseasepatients
AT urianlaura effectoflongperiodtreatmentwitherythropoiesisstimulatingagentsonclinicallyandlaboratoryparametersinhemodialysisautosomaldominantpolycystickidneydiseasepatients
AT cozmaangela effectoflongperiodtreatmentwitherythropoiesisstimulatingagentsonclinicallyandlaboratoryparametersinhemodialysisautosomaldominantpolycystickidneydiseasepatients
AT ciuleigeorge effectoflongperiodtreatmentwitherythropoiesisstimulatingagentsonclinicallyandlaboratoryparametersinhemodialysisautosomaldominantpolycystickidneydiseasepatients
AT patiuioanmihai effectoflongperiodtreatmentwitherythropoiesisstimulatingagentsonclinicallyandlaboratoryparametersinhemodialysisautosomaldominantpolycystickidneydiseasepatients
AT orasanremusaurel effectoflongperiodtreatmentwitherythropoiesisstimulatingagentsonclinicallyandlaboratoryparametersinhemodialysisautosomaldominantpolycystickidneydiseasepatients